|Day Low/High||0.30 / 0.32|
|52 Wk Low/High||0.10 / 1.47|
New York became the 16th state to legalize adult use cannabis.
The potential of legal New York adult-use cannabis sales have been estimated at $1.5 billion a year by 2023.
Ayr Strategies is expanding in a contracting market.
Publicly traded cannabis companies are expected to take big write downs on assets, and here's why it matters.
The quick return to cannabis dispensaries shows that the demise of brick and mortar is a myth.
Several companies that had appeared promising are now blaming the Covid-19 crisis as they fail to turn over a new leaf for the better.
Those that could quickly pivot may earn a new set of customers.
Push to make marijuana-related products 'essential items' could save the business amid coronavirus outbreak.
While 2019 was a decidedly bad year for cannabis stocks, 2020 could be looking more positive.
Here is your Marijuana Moment. Last week, my Trade of the Week (and a half!) was a basket of cannabis stocks -- and I moved to large sized in all of them during the week (Note: The stocks started to roll higher on Friday): My package includes ($7.0...
* My package includes ($7.00), ($5.69), ($5.45), ($2.25) and ($8.15) * It is likely that the maximum tax selling pressure is now virtually over * While technically "The Trade of the Week" - this is my favorite group to benefit from the "January Effe...
If you want to find cheap stocks with great potential to rebound in 2020, the best place to look is marijuana names.
Still, the firm rates the companies mentioned as speculative buys.
While consolidation may be key to the cannabis market in 2019, this IPO is worthy of a deeper dive.
The start to 2019 looks to be much more promising for the cannabis industry than last year.
Gov. Andrew Cuomo's push to legalize adult use of marijuana would be welcome by these companies.
Several cannabis companies are planning to go public this fall.
Matt Karnes, the founder of cannabis industry analytics firm GreenWave Advisors, said that based on his estimates of public sales and dispensary data, MedMen is outpacing the statewide average between $200,000 and $250,000 quarterly revenue per store.
Expect several more firms to list on stock exchanges this year.
MPX is expanding its footprint in several U.S. states.
Medical marijuana may be facing regulatory hurdles across the U.S., but the beauty brands see a future in cannabis too big to ignore.
With tens of millions of dollars in funding, Chicago-based Green Thumb Industries has joined the ranks as one of the larger of publicly traded companies in the budding cannabis space.